RIGging cellular immunity: New RNA based anti-cancer strategy
Date Posted: 16/10/2018
Cancer has become a global health problem due to its increasing incidence. Current cancer therapies are often challenged by non-specific effects and the development of chemoresistance.
A team of researchers from the Korea Advanced Institute of Science and Technology have developed a novel anticancer agent that may overcome both these obstacles. Retinoic acid-inducible gene I, or RIG-I, recognizes double-stranded RNA molecules with certain structural conformations. It then triggers a signal that results in antiviral or anticancer effects. For more information, please clink here.